申请人:Acerta Pharma B.V.
公开号:US20170035881A1
公开(公告)日:2017-02-09
Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
描述了一种白细胞介素-1受体相关激酶4(IRAK4)抑制剂和布鲁顿酪氨酸激酶(BTK)抑制剂的治疗组合。在某些实施例中,本发明提供了包含IRAK4抑制剂和BTK抑制剂组合的药物组合物,以及使用这些药物组合物治疗疾病,特别是癌症的方法。